Evidence map›Paper›PMID 29387609›Full record

ReviewPsoriasis (Auckland, N.Z.)

Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis.

Sahil Sekhon, Caleb Jeon, Mio Nakamura, Di Yan, Ladan Afifi, Tina Bhutani, Ethan Levin

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Psoriasis (Auckland, N.Z.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Sahil SekhonDepartment of Dermatology, University of California, San Francisco, San Francisco, CA, USA.
Caleb JeonDepartment of Dermatology, University of California, San Francisco, San Francisco, CA, USA.
Mio NakamuraDepartment of Dermatology, University of California, San Francisco, San Francisco, CA, USA.
Di YanDepartment of Dermatology, University of California, San Francisco, San Francisco, CA, USA.
Ladan AfifiDepartment of Dermatology, University of California, San Francisco, San Francisco, CA, USA.
Tina BhutaniDepartment of Dermatology, University of California, San Francisco, San Francisco, CA, USA.
Ethan LevinDepartment of Dermatology, University of California, San Francisco, San Francisco, CA, USA.
University of California, San Francisco · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Psoriasis vulgaris is a chronic, immune-mediated systemic disease that affectŝ7.5 million people in the US. It can be treated with many therapies, often in combination, which include topicals, phototherapy, oral systemics, and biologics. Biologic agents target specific components of the immune system involved in the pathogenesis of psoriasis including TNF-alpha, IL-12, IL-17, and IL-23. The biologic ixekizumab, approved for the treatment of moderate-severe plaque psoriasis in the US, targets IL-17. This review describes the role of IL-17 in psoriasis, the mechanism by which ixekizumab targets this cytokine, and the clinical utility of ixekizumab.

Indexed as

anti-IL-17biologicsIL-17ixekizumabpsoriasis

Identifiers

PMID29387609
PMCPMC5774608
OpenAlexW2768472155

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.